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Abstract.
As is diabetes itself, diabetic vasculopathy is a multi-factor disease. Studies conducted
in this lab revealed advanced glycation endproducts (AGE) as the major environmental
account for vascular cell derangement characteristic of diabetes, and the receptor for
AGE (RAGE) as the major genetic factor that responds to them. AGE fractions that
caused the vascular derangement were proven to be RAGE ligands. When made
diabetic, RAGE-overexpressing transgenic mice exhibited the exacerbation of the
indices of nephropathy, and this was prevented by the inhibition of AGE formation. We
also created RAGE-deficient mice. They showed marked amelioration of diabetic
nephropathy. Extracellular signals and nuclear factors that induce the transcription of
human RAGE gene were also identified, which would be regarded as risk factors of
diabetic complications. Through an analysis of vascular polysomal poly(A)+RNA, we
came across a novel splice variant coding for a soluble RAGE protein, and named it
endogenous secretory RAGE (esRAGE). esRAGE was able to capture AGE ligands and
to neutralize the AGE action on endothelial cells, suggesting that this variant has a
potential to protect blood vessels from diabetes-induced injury. The AGE-RAGE system
should thus be regarded as a candidate molecular target for overcoming this life- and
QOL-threatening disease.
Introduction
The number of peoples who are suffering from diabetes mellitus is steadily increasing.
Before being lethal, quality of life (QOL) is greatly impaired in the patients with
diabetes due to vascular complications like retinopathy and nephropathy. To understand
how blood vessels are impaired in the diabetic state is, therefore, crucially important. As
is diabetes per se, diabetic omplications are caused by multiple environmental nd
genetic factors, and we should identify such accounts one by one. Those efforts should
reveal effective molecular targets for our overcoming this life- and QOL-threatening
disease.
1. Advanced glycation endproducts (AGE) and the receptor for AGE (RAGE)
    In 1912, Maillard described that reducing sugars like glucose can react non-
enzymatically with the amino groups of proteins to form Schiff bases and then Amadori
compounds. These early glycation products undergo further reactions, including
dehydration, condensation and crosslinking, yielding irreversible protein derivatives
termed AGE. The AGE formation and accumulation are most accelerated under
diabetes. Non-enzymatic pathways that are distinct from the classical Maillard reaction
but can also yield AGE have recently been known (1). They use short-chain carbonyl
compounds, uch as glyceraldehyde, glyoxal, glycolaldehyde, methylglyoxal nd 3-
deoxyglucosone, as intermediates. These short-chain aldehydes are more reactive than
glucose, taking shorter time period to accomplish the AGE formation, and do occur in
human bodies. Most AGE structures derived from the short-chain carbonyl remain to be
defined.
   Cellular receptors to which AGE can bind have been described. Among them is
RAGE, which was initially isolated from bovine lung (2). It belongs to the
immunoglobulin superfamily, having three immunoglobulin-like domains in the N-
terminal extracellular segment, one transmembrane region and a short C-terminal
intracytoplasmic stretch. RAGE is also known as a multi-ligand receptor not only for
AGE but also for amphoterin, S100 proteins, amyloid-b proteins and transthyretin.
   We prepared AGE by incubating BSA with glyceraldehyde, glyoxal,
glycolaldehyde, methylglyoxal and 3-deoxyglucosone, and tested their abilities to bind
purified human RAGE protein using a BIACORE surface plasmon resonance system.
Glyceraldehydes- and glycolaldehyde-derived AGE were found to be associated with
the sensor chip, as the control glucose-derived AGE was. Apparent dissociation
constant (Kd) values of RAGE interaction with glyceraldehyde-derived AGE and
glycolaldehyde-derived AGE were estimated to be ~300 nM and ~1.4 m M, respectively,
when assessed either by the BIACORE assay or by Scatchard analysis with intact cells
and 125I-labeled AGE. The results indicated that glyceraldehydes- and glycolaldehyde-
derived AGE are new RAGE ligands.
   We thus next examined whether glyceraldehydes- and glycolaldehyde-derived AGE
inhibit the growth of human pericytes; pericyte loss is a hallmark of diabetic retinopathy.
As a result, glyceraldehydes- and glycolaldehyde-derived AGE were found to
significantly decrease human brain pericyte synthesis of DNA at lower concentrations
than did glucose-derived AGE. On the contrary, when administered to EC, glucose-,
glyceraldehydes- and glycolaldehyde-derived AGE significantly increased viable cell
numbers and upregulated the levels of VEGF mRNA. The results indicate that the
RAGE-engaging AGE fractions occurring in our internal milieu should be regarded as
an environmental account for vascular injury in diabetes.
2. RAGE transgenic mice
   To evaluate in vivo the hypothesis that the AGE-RAGE system may participate in
the development of diabetic vascular complications, We created transgenic mice that
overexpress human RAGE proteins in vascular cells, and crossbred them with another
transgenic mouse line that develops insulin-dependent diabetes early after birth (3). The
resultant double transgenic mice showed statistically significant increases in kidney
weight, albuminuria, glomerulosclerosis index and serum creatinine compared with the
diabetic control, while blood glucose, hemoglobin A1c and serum AGE levels were
essentially invariant between the two groups. The increases in serum creatinine and
sclerosis index were effectively prevented with (±)-2-isopropylidenehydrazono-4-oxo-
thiazolidin-5-ylacetanilide, an inhibitor of AGE formation. Indices diagnostic of
diabetic retinopathy were also most prominent in the double transgenic. Thus, this
transgenic approach has supported the concept that AGE-RAGE system plays an active
role in the development of diabetic complications, and has developed a useful animal
model for testing remedies.
   Further, mice deficient for RAGE showed amelioration of diabetic nephropathy, as
evidenced by loss of nephromegaly, significant decrease in albuminuria, improved
glomerulosclerosis and no elevation of serum creatinine. This again emphasizes that
RAGE is functionally involved in the development of diabetic nephropathy.
3. Regulation of human RAGE gene
   In light of the findings with RAGE transgenic mice, it is reasonable to assume that
upregulation of the endogenous RAGE gene would aggravate diabetic vascular
derangement. Accordingly, we screened factors that can influence the EC level of
RAGE mRNA. We identified three inducers of RAGE gene transcription: AGE ligands
themselves, tumor necrosis factor-a  (TNF a ) and 17b -estradiol (4). TNF-a  has been
known to be responsible for insulin resistance. The action on RAGE gene unveiled
another side of this cytokine; that is, an increased TNF-a  level in diabetic patients may
worsen diabetic complications through RAGE induction. Between the AGE and RAGE
a positive feedback loop may exacerbate diabetic vasculopathy. The RAGE gene
activation by estradiol may provide a biochemical basis for the well-known fact that
pregnancy worsens diabetic complications.
4. esRAGE
   We analyzed poly(A)+RNA isolated from polysomes of human EC and pericytes,
and isolated previously undescribed splice variants of RAGE mRNA (5). Three major
variants were identified: the known full-length membrane-bound form, a novel N-
terminally truncated membrane-bound form and a novel C-terminally truncated soluble
form. The ratio of expression of these variants differed from one cell type to another; C-
truncated > full-length = N-truncated in EC; full-length > N-truncated > C-truncated in
pericytes. We named the C-truncated form “esRAGE (endogenous secretory RAGE)”.
esRAGE would be cytoprotective, because it is able to capture AGE outside cells. In
effect, this variant was found to effectively neutralize the AGE action on EC and does
exist in human circulation. An enzyme-linked immunosorbent assay system for
esRAGE has been developed, and, with it, diabetic subjects with or without
complications are now being screened.
Conclusion
   AGE are senescent proteins that accumulate during prolonged diabetic exposure,
and can also engage cell surface RAGE, this resulting in the deterioration of vascular
functions. The AGE-RAGE system thus should be a candidate target for overcoming
this life- and QOL-threatening disease.
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